Abstract
The iCAP is a tool for blood-based diagnostics that addresses the low signal-to-noise ratio of blood biomarkers by using cells as biosensors. The assay exposes small volumes of patient serum to standardized cells in culture and classifies disease by AI analysis of gene-expression readouts from the cells. It simplifies the complexity of blood into a concise readout in a scalable cell-based assay. We developed the LC-iCAP as a rule-out test for nodule management in CT-based lung cancer screening. The assay achieved an AUC of 0.63 (95% CI 0.50-0.75) in retrospective-blind-temporal validation. When integrated with CT data after validation, it demonstrated potential to reduce unnecessary follow-up procedures by significantly outperforming the Mayo Clinic model with 90% sensitivity, 67% specificity and 95% NPV using an estimated 25% prevalence. Analytical validation established LC-iCAP reproducibility and identified unwanted variation from long-term serum storage suggesting a prospective study design could enhance performance.
Competing Interest Statement
Competing interests: RJL, JJS, JDB, GAW, MDD, and YQ are current and/or past employees of PreCyte and have equity interests in the company. JDA and RJL serve as board members with equity interests in PreCyte. LRM and SAD also have equity interests in PreCyte. FJD acts as a consultant and/or has performed contracted work for PreCyte. JJS, RJL, JDA, JDB, MDD, GAW, and FJD have filed patent applications related to the compositions, methods, kits, and processes described in this manuscript in the US and in foreign jurisdictions. SD and AV declare no conflicts of interest.
Funding Statement
Research reported in this publication was supported by the National Cancer Institute (NCI) and National Institute of Aging (NIA) of the National Institutes of Health (NIH) under Award Numbers R43CA203455, R44CA203455 and R44AG051282 to PreCyte, the National Institute of Environmental Health Sciences (NIEHS) of the NIH under Award Number P30ES013508 to the University of Pennsylvania, and the NCI of the NIH under award number P30CA068485 and NCI-U01CA152662 to Vanderbilt University. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
WCG IRB gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are either contained in the manuscript or supplementary tables and figures except for complete Raw and processed RNAseq data. Raw and processed RNAseq data have been submitted to GEO repository and will be publicly available after peer review.
Abbreviations
- AUC
- area under the ROC curve
- CT
- computed tomography
- DEG
- differentially expressed gene
- DMOG
- dimethyloxalylglycine
- GSEA
- gene set enrichment analysis
- iCAP
- indicator cell assay platform
- NPV
- negative predictive value
- ROC
- receiver operator characteristic
- MCED
- multi-cancer early detection
